key: cord-0854081-my23bi7m authors: Cairns, Dana M.; Dulko, Dorothy; Griffiths, Jeffrey K.; Golan, Yoav; Cohen, Theodora; Trinquart, Ludovic; Price, Lori Lyn; Beaulac, Kirthana R.; Selker, Harry P. title: Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial date: 2022-02-09 journal: JAMA Netw Open DOI: 10.1001/jamanetworkopen.2021.44942 sha: bbaed68bc13e596ccaee6ed8e35f22dc0028a55a doc_id: 854081 cord_uid: my23bi7m IMPORTANCE: Oral anthelmintic niclosamide has potent in vitro antiviral activity against SARS-CoV-2. Repurposed niclosamide could be a safe and efficacious COVID-19 therapy. OBJECTIVE: To investigate whether niclosamide decreased SARS-CoV-2 shedding and duration of symptoms among patients with mild to moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This randomized, placebo-controlled clinical trial enrolled individuals testing positive for SARS-CoV-2 by polymerase chain reaction with mild to moderate symptoms of COVID. All trial participants, investigators, staff, and laboratory personnel were kept blind to participant assignments. Enrollment was among individuals reporting at Tufts Medical Center and Wellforce Network in Massachusetts for outpatient COVID-19 testing. The trial opened to accrual on October 1, 2020; the last participant enrolled on April 20, 2021. Trial exclusion criteria included hospitalization at time of enrollment or use of any experimental treatment for COVID-19, including vaccination. Enrollment was stopped before attaining the planned sample size when COVID-19 diagnoses decreased precipitously in Massachusetts. Data were analyzed from July through September 2021. INTERVENTIONS: In addition to receiving current standard of care, participants were randomly assigned on a 1:1 basis to receive niclosamide 2 g by mouth daily for 7 days or identically labeled placebo at the same dosing schedule. MAIN OUTCOMES AND MEASURES: Oropharyngeal and fecal samples were self-collected for viral shedding measured by reverse-transcriptase–polymerase-chain-reaction on days 3, 7, 10, and 14, and an additional fecal sample was collected on day 21. A telehealth platform was developed to conduct remote study visits, monitor symptoms, and coordinate sample collection via couriers. The primary end point was the proportion of participants with viral clearance in respiratory samples at day 3 based on the intention-to-treat sample. Mean times to viral clearance and symptom resolution were calculated as restricted mean survival times and accounted for censored observations. RESULTS: Among 73 participants, 36 individuals were enrolled and randomized to niclosamide and 37 individuals to placebo. Participant characteristics were similar across treatment groups; among 34 patients receiving placebo and 33 patients receiving niclosamide in the intention-to-treat sample, mean (SD) age was 36.0 (13.3) years vs 36.8 (12.9) years and there were 21 (61.8%) men vs 20 (60.6%) men. The overall mean (SD) age was 36.4 (13.0) years. For the primary end point, 66.67% (95% CI, 50.74% to 81.81%) of participants receiving niclosamide and 55.88% (95% CI, 40.27% to 72.73%) of participants receiving placebo had oropharyngeal SARS-CoV-2 clearance at day 3 (P = .37). Among 63 participants with symptoms, niclosamide did not significantly shorten symptom duration, which was 12.01 (95% CI, 8.82 to 15.2) days in the niclosamide group vs 14.61 (95% CI, 11.25 to 17.96) days in the placebo group (mean difference, −2.6 [95% CI, −7.23 to 2.03] days). Niclosamide was well-tolerated; the most commonly reported adverse events in the placebo and niclosamide groups were headaches (11 patients [32.4%] vs 7 patients [21.2%]; P = .31) and cough (8 patients [23.5%] vs 7 patients [21.2%]; P = .82). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, there was no significant difference in oropharyngeal clearance of SARS-CoV-2 at day 3 between placebo and niclosamide groups. Confirmation in larger studies is warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04399356 SchemA 3 41 1. Participants will be identified as those reporting to Tufts Medical Center, Wellforce and CRN sites for outpatient COVID-19 testing. Patients with SARS-CoV-2 positive test results will be provided the option to participate in our study. The Study Team will enroll and randomize patients into the study after the patient has a confirmed positive test result and meets all the inclusion and none of the exclusion criteria. Additional sites and/or social media may be used to enhance recruitment. The study will be listed at www.clinicaltrials.gov. Participants in the treatment arm will receive niclosamide 2 grams orally once daily for 7 days in addition to current standard of care treatment. Those in the control group will receive placebo by mouth in the same numbers of pills on day 1 and daily for 6 more days (total 7 days of treatment) in addition to current standard of care treatment. Fecal samples and oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14 and 21 (fecal sample only). A baseline fecal and oropharyngeal sample will be obtained on Day 1 prior to starting dosing of niclosamide/ placebo. The study is estimated to complete enrollment within 2-months of initiation of enrollment; however, enrollment will remain open until the study goal is met. The duration of the entire project is anticipated to be a maximum of 4 months. Individual participant will complete all participant visits within 30 days. Adverse events will be monitored and collected by the Study Team from the point of signed consent until 7 (for non-serious adverse events) or 30 days (for serious adverse events) after the last day of study participation. severely ill due to this disease. A screening and enrollment log will be maintained. There is no expectation of severe adverse outcomes or reactions due to a patient being treated with 274 niclosamide. Niclosamide is generally well tolerated and has been prescribed clinically for over 30 years. Reported AEs in current use are mild and include nausea and diarrhea. All participants will be given 276 access to contact information of the Study Team, and any adverse reactions will be reported as required 277 by the protocol. 278 279 Tufts Medical Center seeking COVID-19 testing. All patients will be provided the option to participate in 306 our study pending a positive SARS-CoV-2 test result. The Study Team will enroll and randomize patients 307 into the study after the patient has a confirmed positive test result and meets all the inclusion and none 308 of the exclusion criteria. Participants in the treatment arm (n= 100) will receive niclosamide 2g orally daily for 7 days in addition 310 to current standard of care treatment. Those in the control group (n=100) will receive placebo by 311 mouth in the same numbers of pills on day 1 and daily for 6 more days (total 7 days of treatment) in 312 addition to current standard of care treatment. Laboratory PCR testing will be performed at Tufts Medical Center laboratory or other CLIA certified lab. A study recruitment brochure will be distributed at the associated Wellforce and CRN sites. A study 320 poster will be available for affiliated outpatient sites that perform COVID testing. Both will include a QR 321 code for ease of accessing study information. In addition, nurses who provide results to patients (by 322 phone) who have tested positive at Tufts Medical Center outpatient will provide basic, scripted study 323 information to potential participants. This information will include contact information for the Study Team and has been submitted to the Tufts IRB. Participation at Wellforce and CRN sites will be limited 325 to distribution of study brochures and display of posters and (on a site by site basis) provision of PHI 326 (name and contact phone number of potential participants who express interest in the study). This 327 information will be provided to the Tufts Study Team via a secure, encrypted message. Revisions to the 328 study brochure or any recruitment material will be provided to the site contact by the Tufts Study Team. No research activities will be conducted at the associated sites (e.g., informed consent, study visits, data 330 collection, data entry, data analysis, etc.). All study activity will be conducted by the Tufts Study Team. The Tufts Study Team will keep record of the site of origin for each enrolled study participant. This de-332 identified, aggregated recruitment data will be provided to each site as requested by the site. A study recruitment brochure will be distributed in the community. A study poster will be available for 335 affiliated outpatient sites that perform COVID testing. Both will include a QR code for ease of accessing 336 study information. In addition, nurses who provide results to patients (by phone) who have tested 337 positive will provide basic, scripted study information to potential participants. This information will 338 include contact information for the Study Team and has been submitted to the Tufts IRB. Control Group, in accordance with a computer-generated schedule prepared by a biostatistician. The 347 randomization schedule will be incorporated into the REDCap Electronic Data Capture (EDC) system. Randomization will then be performed by study personnel directly in the EDC system. Study personnel 349 will be instructed not to randomize until participant has been confirmed to meet all inclusion/exclusion 350 criteria on treatment day 0. Oropharyngeal and fecal swabs will be collected at days 1 (baseline), 3, 7, 10, and 14 of the study. An 512 additional fecal specimen will be collected at day 21. In the case of oropharyngeal samples, care will be 513 taken to ensure that sampling methods are consistent for each individual patient across all included 514 timepoints, to limit any bias due to potential differences in viral load. A HIPPA compliant telehealth platform; e.g., Doximity, will be used to conduct remote study visits. Twice daily a list of COVID-19 positive patients will be generated by the Niclosamide may be taken on an empty stomach (either 1 hour before or 2 hours after a meal). However, to prevent stomach upset, it is best taken after a light meal (for example, breakfast). Participants will be advised to avoid alcohol consumption during study treatment period. There will be no significant preparation. Both niclosamide and placebo tablets will be dispensed in 615 blinded blister packages and labeled in accordance with state and federal regulation. Participants who sign informed consent and meet all inclusion and exclusion criteria will be randomized 619 on Treatment Day 0 in a 1:1 ratio to either the Treatment Group or the Control Group, in accordance 620 with a computer-generated schedule prepared by a biostatistician. The randomization schedule will be 621 incorporated into the REDCap EDC system. Randomization will then be performed by study personnel 622 directly in the EDC system. Study personnel will be instructed not to randomize until participant has 623 been confirmed to meet all inclusion/exclusion criteria on treatment day 0. As all members of the Study Team will be blinded, Tufts Investigational Drug Services (IDS) will be 626 unblinded and will dispense both the Niclosamide and placebo. The study intervention (niclosamide) 627 and placebo will be packaged and as indistinguishable as possible. The study site will not supply rescue medication. A participant will be considered lost to follow-up if he or she fails to complete more than (2) scheduled 715 telehealth visits and is unable to be contacted by the study staff. The following actions must be taken if a participant fails to attend a required telehealth visit:  The Study Team will attempt to contact the participant and reschedule the missed visit and 719 counsel the participant on the importance of maintaining the assigned visit schedule and 720 ascertain if the participant wishes to and/or should continue in the study.  Before a participant is deemed lost to follow-up, the investigator or designee will make every 722 effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, 723 a certified letter to the participant's last known mailing address or local equivalent methods). These contact attempts will be documented in the participant's medical record or study file.  Should the participant continue to be unreachable, he or she will be considered to have 726 withdrawn from the study with a primary reason of lost to follow-up.  For participants considered lost to follow-up, the CRF will be completed up to the last contact Remote clinical follow-up will occur at the following time points: Days 1, 2, 3, 7, 10, 14, 21 and 30. The following procedures will be performed at all follow-up visits, expected to be done by tele-medical medical condition or intervention, which could explain the occurrence of such an event. There is no clear relationship between the AE and the drug or study procedure; however, one cannot conclude that there is no relationship. There is no relationship between the AE and the drug or study procedure. This may include but is not limited to the incident being an expected outcome of a previously existing or concurrent disease, concomitant medication or procedure the participant experienced. During the Informed Consent discussion, the MD study Investigator will ask women of childbearing 916 potential if they are pregnant. That yes/ no response will be recorded. We will not exclude women who 917 are of childbearing years or pregnant. We will collect pregnancy status information at the time of To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline: • UPs that are SAEs will be reported to the IRB within 5 working days of the investigator becoming 958 aware of the event. • A Study Team evaluation of an UP will be performed with a report of results of such evaluation 960 will be provided to the reviewing IRB by the PI within 5 working days. • All other Reportable New Information will be reported to the IRB as per the policy. For categorical variables, results within each arm will be summarized with participant counts, 1015 percentages, and 95% confidence intervals. The differences between the two treatment arms will be 1016 summarized with the difference in percentages and the asymptotic 95% confidence interval for the 1017 difference of two percentages. Survival analysis techniques will be used to analyze the time-to-event variables. Survival curves will be 1020 constructed using Kaplan-Meier estimates. Log-rank test results will be computed for comparison of 1021 survival distributions. Summary tables for safety and efficacy endpoints will include event rates (Kaplan- Meier estimates of event rates), relative risk, confidence interval for the relative risk, the difference in 1023 means/rates, the confidence interval for difference in means/rates, and the p-value. For the primary efficacy endpoint, respiratory Clearance at Day 3 will be summarized by treatment 1027 group and the difference will be tested using a two-sided Fisher's Exact Test at the 0.05 significance 1028 level. The corresponding confidence interval for the difference in proportions will be calculated. The study participant's contact information will be securely stored at each clinical site for internal use 1204 during the study. At the end of the study, all records will continue to be kept in a secure location for as 1205 long a period as dictated by the reviewing IRB, Institutional policies, or sponsor requirements. The Principal Investigator will be responsible to ensure the study is conducted in accordance with the 1207 protocol, Good Clinical Practice (GCP), applicable regulatory requirements, and that the data recorded is 1208 valid. To achieve this objective, the study will be continuously monitored, and the study conduct The collection of personal patient information will be limited to the amount necessary to achieve the 1220 aims of the research, so that no unneeded sensitive information is being collected. Data from the EDC will be exported into Excel or SAS file format (password protected), which will then 1222 be used for data analysis. Only de-identified, not including the participant's contact or identifying 1223 information data will be used for data analysis. Trial design 29 The trial is a single-center, randomized, parallel-group, placebo-controlled trial. Treatment allocation 30 was a 1:1 ratio. Patients were randomized to either niclosamide (2 grams orally once daily for 7 days) or 31 matched placebo control. 32 The random allocation sequence was computer-generated by a biostatistician. Randomization was 34 stratified into three strata: Tufts lab and non-Tufts lab. We used blocking (block size 4). The random 35 allocation sequence was implemented into the Redcap Electronic Data Capture (EDC) system which 36 guaranteed concealment of the sequence until treatments were assigned. 37 For the primary efficacy endpoint of respiratory virologic clearance at Day 3 measured by oropharyngeal 39 viral shedding, 40 participants in each group achieve 89.1% power to detect a difference between the 40 group proportions of 35%. We assumed that 50% and 15% of participants in the niclosamide and 41 placebo groups would have a negative test on Day 3. The calculation was under a two-sided Fisher's 42 Exact Test and a significance level of 0.05. 43 For all objectives, we test for superiority of niclosamide against placebo. 45 We did not plan or perform any interim analyses. 47 The trial was closed to recruitment on June 22, 2021 due to the effective ending of the COVID-19 48 epidemic in Massachusetts resulting in lack of available candidates. 49 Final analysis will take place in one stage, when every patient has reached 30-day follow-up and data for 51 the primary and secondary endpoints have been received and cleaned. 52 Primary efficacy endpoint: respiratory viral clearance at Day 3. 54 Secondary efficacy endpoints 55 • Fecal viral clearance at Day 14. 56 • Reduction in viral shedding as measured by oropharyngeal swab on days, 3, 7, 10, 14. 57 • Reduction in fecal viral shedding as measured by fecal PCR on days, 3, 7, 10, 14 and 21. 58 • Progression to severe COVID. 59 • Resolution of symptoms (including but not limited to fever, cough, fatigue). 60 Confidence intervals and P values 62 All statistical tests will be 2-sided and will be performed using a 5% significance level. We will derive 95% 63 two-sided confidence intervals. 64 In this study, four pills are to be taken daily for 7 days. Compliance is assessed by the percentage of 66 subjects who have taken the scheduled number of pills: 67 % compliance = 100x (number of pills taken / 28 pills supposed to have been taken). 68 We will summarize compliance by randomization group: mean % compliance as well as number and 69 percentage of participants with more than 80% compliance (24 pills out of 28). 70 Similarly, we will assess compliance with oropharyngeal and fecal sampling. 71 Protocol deviations will be classified into: 72 • PCR > 3 days before randomization 73 • taking the first dose before the first telehealth visit 74 • missing at least 1 telehealth visit 75 • collecting at least one oropharyngeal sample outside of window (day 1, 3, 7, 10, 14 ±1 day) 76 • collecting at least one fecal sample outside of window (day, 1, 3, 7, 10, 14, 21 ±1 day) 77 • collecting less than 5 oropharyngeal samples 78 • collecting less than 6 fecal samples 79 • taking the wrong dose at least once 80 • taking the wrong dose at least once 81 • missing a dose at least once 82 • expected assessments not completed during at least one telehealth visit (e.g., physician disconnected) 83 Protocol deviations were classified prior to unblinding of treatment assignment. We will report detailed 84 protocol deviations per participant. We will summarize the number and percentage of participants with 85 protocol deviations by treatment group with details of type of deviation. 86 We will exclude participants who withdrew consent after randomization but before taking any sample or 88 pill. 89 The intention-to-treat (ITT) population will include all randomized patients according to the treatment 90 they were randomized to receive. 91 If a participant has several samples on the same day, we will consider the result to be positive if at least 124 one of the sample results is positive, and negative otherwise. 125 In table 1, we illustrate possible patterns of time to viral clearance and time post-viral clearance. We 126 illustrate samples available on days per protocol. But, according to our definition of clearance, time to 127 clearance and time post-clearance are identifiable even if samples taken on different days. 128 In absence of deviations from protocol, we expect oropharyngeal sample results on 5 distinct days (day 131 1, 3, 7, 10, 14) and fecal sample on 6 distinct days (day 1, 3, 7, 10, 14, 21). Some participants may have 132 samples on less than 5 or 6 distinct days. We will identify the occurrence of viral clearance as defined 133 above based on available samples. If clearance is not observed, we will censor participants at their last 134 available sample. In Table 2 , we illustrate possible patterns of non-available sample results. 135 Primary analysis 139 The primary endpoint is viral clearance in respiratory samples at day 3. The primary analysis will be 140 based on the ITT population (i.e., all randomized participants). We will estimate the cumulative 141 probability of being in clearance in each randomization group by using the Kaplan-Meier estimator. We 142 will compare the cumulative probability of clearance at day 3 between the two groups by using a chi-143 square test based on a log(− log(·)) transformation for the survival function. {log (−log (Ŝ 1 (t))) − log (−log (Ŝ 0 (t)))} 2 1 ( ) 2 log (Ŝ 1 (t)) 2 +̂0 ( ) 2 log (Ŝ 0 (t)) 2 Under the null hypothesis of no difference in probability of being in clearance between the two groups, 146 the statistic of test is asymptotically χ 1 2 -distributed. We will provide the between-group difference in 147 probability of viral clearance at day 3 and the associated 95% confidence interval based on the cloglog 148 transformation of the survival function. 149 In secondary analyses, 151 1) We will compare the respiratory clearance probability functions from day 1 to 14 between the 152 two groups by using a log-rank test. 153 2) We will calculate the area under each respiratory clearance-free probability curve which gives 154 the mean time to viral clearance up to day 14. We will estimate the mean difference in time 155 post-viral clearance between groups and the associated 95% confidence interval. 156 3) We will compare how the proportion of negative oropharyngeal sample results evolved over 157 time between treatment groups by using random-intercepts logistic regression models for 158 longitudinal binary outcome data. 159 4) We will repeat the primary analysis for fecal viral clearance at day 14. 160 5) We will repeat the secondary analyses 1)-3) above for fecal viral clearance. 161 6) We will repeat the primary and secondary analysis by considering the combined oropharyngeal 162 and/or fecal sample results. If both types of samples are available on a given day, we will 163 consider the result to be positive if at least one of the sample results is positive, and negative 164 otherwise. If only one type of sample is available on a given day and it is positive (respectively 165 negative), the result will be positive (negative) for that day. 166 7) We will compare the proportion of participants who progressed to severe COVID disease 167 between groups. 168 8) We will compare the proportions of participants free of symptoms. We will include participants 169 who reported symptoms on Day 1 and we will assess the time to symptom resolution (symptom 170 no longer reported). We will analyze 8 symptom categories described in Table 3 . 171 9) We will repeat the primary and secondary analyses for viral clearance in the mITT population. 172 10) We will repeat the primary and secondary analyses for viral clearance in the per protocol 173 population. 174 175 We pre-specified subgroup analyses of viral clearance and symptom resolution according to BMI (<25 177 kg/m 2 vs. ≥25 kg/m 2 ) and according to diabetes. 178 In exploratory analyses, we will repeat the primary and secondary analyses of viral clearance by 180 calculating the time to viral clearance from the confirmatory PCR before randomization. 181 Moreover, in an analysis blinded to random allocation, we will analyze the trajectories of oropharyngeal 182 and fecal sample results. In particular, we will identify participants with a negative test result followed 183 by at least one positive test result (as defined by the DSL COVID-19 Assay); we will examine the Ct values 184 of the positive test results following a negative test result. We will repeat the primary and secondary 185 analyses by considering alternative thresholds to define a positive result, based on the blinded review of 186 data. 187 We also will perform longitudinal analyses to assess the between-group difference in gene expression 188 over time. For each participant and each sample, we will calculate the difference in expression (in terms 189 of quantification cycle) between the target gene (SARS-CoV-2 specific nucleocapsid N1; panspecific CoV 190 nucleocapsid N3; or SARS-CoV-2 spike) and a reference gene (RNase P): ΔCq= Cq(target 191 gene)−Cq(reference gene). We will create spaghetti plots in each randomization group with lowess 192 smoother curve superimposed. We will create heatmaps of ΔCq values scaled to the mean and standard 193 deviation within each participant. We will use linear mixed models, including a term for the group, a 194 term for time, and group x time interaction term and a subject-level random intercept, to compare the 195 trajectories in normalized expression between groups over time. 196 Prolonged presence of SARS-CoV-2 viral 1399 RNA in faecal samples Identification of antiviral 1401 drug candidates against SARS-CoV-2 from FDA-approved drugs Intracellular Vesicles by Niclosamide Inhibits Multiple Steps of the Dengue Virus Life Cycle In 1405 Niclosamide rescues microcephaly in a 1407 humanized in vivo model of Zika infection using human induced neural stem cells Niclosamide: Beyond an antihelminthic 1410 drug Dual activity of 1416 niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis 1417 (Beijing) Niclosamide is 1419 a proton carrier and targets acidic endosomes with broad antiviral effects Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections. Sci Rep Antiviral 1425 activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission Broad Spectrum Antiviral Agent Niclosamide and Its 1428 Therapeutic Potential Identification of small-molecule inhibitors of Zika virus infection and 1433 induced neural cell death via a drug repurposing screen Inhibition of severe acute respiratory syndrome 1436 coronavirus replication by niclosamide Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral 1441 Entry. Viruses Niclosamide suppresses macrophage induced 1444 inflammation in endometriosis Repurposing an old drug for new use: 1446 Niclosamide in psoriasis-like skin inflammation Effects of salinomycin and niclosamide on small cell lung cancer and 1449 small cell lung cancer circulating tumor cell lines Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells In 1452 Vitro and In Vivo Niclosamide alleviates pulmonary fibrosis 1454 in vitro and in vivo by attenuation of epithelial-to-mesenchymal transition Wnt/beta-catenin signaling: A drug repurposing study Niclosamide repurposed for the 1457 treatment of inflammatory airway disease Drug 1462 Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways Phase II trial to 1465 investigate the safety and efficacy of orally applied niclosamide in patients with metachronous 1466 or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial Niclosamide a new chemotherapy 1470 agent? Pharmacokinetics of the potential anticancer drug in a patient cohort of the NIKOLO trial A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative 1473 Proctosigmoiditis Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among 1480 Patients with Coronavirus Disease 2019 -United States Early release of selected estimates based on data from the 2018 National Health 1483 Interview Survey. US Department of Health and Human Services Epidemiological, clinical and virological characteristics of 74 cases of 1489 coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms Tissue distribution of 1492 ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS 1493 pathogenesis Pharmacokinetics of Anti-SARS-CoV Agent Niclosamide and Its Analogs New life for an old 1498 drug: In vitro and in vivo effects of the anthelmintic drug niclosamide against Toxoplasma gondii 1499 RH strain The Anthelmintic Drug 1501 Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli Host-1504 targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without 1505 disrupting the gut microbiota Long-Term Survival Following Multivessel Revascularization in Patients 1509 With Diabetes: The FREEDOM Follow-On Study Development, characterization and evaluation of in vivo anti-tumor activity of niclosamide 1513 nanoliposomes against colon carcinoma Clinical features of patients infected with 2019 novel 1518 coronavirus in Wuhan Is SARS-CoV-2 Also an Enteric Pathogen With Potential Fecal-Oral 1520 Transmission? A COVID-19 Virological and Clinical Review Clinical and virological data of the first cases of COVID-19 1522 in Europe: a case series Niclosamide, an antihelmintic drug, enhances efficacy of PD-1524 PD-L1 immune checkpoint blockade in non-small cell lung cancer Two cases of COVID-19 with 1527 positive salivary and negative pharyngeal or respiratory swabs at hospital discharge: A rising 1528 concern Saliva is more 1532 sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs Missing Cq value can 197 correspond to a true Cq value above the Cq threshold. Alternatively it can correspond to zero expression 198 (no amplification above the Cq threshold) We will also consider the following modified ITT analyses of viral clearance: 202 -for the analysis based on oropharyngeal samples, fecal samples, and both types, we will include 203 participants who took at least one pill, have a positive test result at any time during the trial and -for the analysis based on fecal samples, we will include participants who took at least one pill, have a 206 positive oropharyngeal test result and have Day 3 fecal sample results available for analysis Fecal viral clearing at day 14 will be summarized by treatment group and the difference will 1040 be tested separately for each day using a two-sided Fisher's Exact Test.1041 1042• Respiratory viral shedding as measured on days 1, 3, 7, 10, 14 will be compared between 1043 treatment groups using repeated measures analysis.1044 1045• Fecal viral shedding as measured on days 1, 3, 7, 10, 14 and 21 will be compared between 1046 treatment groups using repeated measures analysis. We plan to consider additional analysis approaches including but not limited to: time to negative COVID-1049 19 test as determined by PCR using oropharyngeal and/or fecal samples; longitudinal analysis of 1050 continuous measures such as body temperature and O2 saturation; The proportion of participants in 1051 each treatment group who progress to severe COVID disease will be compared using a two-sided z test 1052 with continuity correction. The corresponding confidence interval for the difference in proportions will 1053 be calculated. All secondary endpoint analyses will be performed for the mITT and PP populations at the 0.05 1056 significance level. No adjustment for multiple testing will be performed. Quality control (QC) procedures will be implemented beginning with the data entry system and data QC 1309 checks that will be run on the database will be generated. Any missing data or data anomalies will be 1310 communicated to study PI or designee for resolution. The per-protocol population will a subset of the participants in the full analysis (ITT) set who took at 92 least 80% of study intervention. 93The modified ITT population will include participants who took at least one pill, have a positive 94 oropharyngeal test result on Day 1 and have Day 3 oropharyngeal sample results available for analysis. 95The safety population will include participants who took at least one pill. 96 Screening, eligibility, recruitment, and withdrawal/follow-up 98We will use a CONSORT flow diagram to summarize the number of participants who were: 99• assessed for eligibility at screening 100• eligible at screening 101• eligible and randomized 102• withdrew prior to received first dose 103• randomized and included in the primary analysis 104The flow diagram will also show the numbers who were eligible but not randomized, who did not 105 receive the randomized allocation, who were lost to follow-up, who discontinued the intervention, and 106we will describe the reasons. 107Baseline patient characteristics 108Participants will be described at the time of randomization with respect to age, sex, race/ethnicity, 109COVID-19 symptoms, smoking, obesity/overweight, asthma, COPD, cancer, cerebrovascular disease, 110CKD, cystic fibrosis, heart conditions, hypertension, immunocompromised state, liver disease, neurologic 111conditions, pulmonary fibrosis, sickle cell disease, thalassemia, diabetes, both overall and separately for 112 the two randomization groups. We will summarize categorical data by numbers and percentages. We 113 will summarize continuous data by mean, SD (or median, Q1-Q3 if data are skewed). We will not 114 undertake tests of statistical significance. We will note the clinical importance of any imbalance. 115 Outcome definitions 117Viral clearance 118Respiratory viral clearance is defined as the first day a participant's oropharyngeal sample result is 119 negative, provided that none of the subsequent oropharyngeal sample results are positive. In primary 120analyses, we will use sample results (positive or negative) as returned by Diagnostic Solutions 121Laboratory. We will use a similar definition for fecal viral clearance. We will calculate the time to 122 clearance since Day 1. 123 For the longitudinal analyses, we will perform sensitivity analyses by imputing data according to 209 sequential multiple imputation 210 The number (and percentage) of patients experiencing each adverse event will be presented, both for 212 the overall safety population and in each randomization group. We will not perform statistical testing. 213We will assess the clinical significance of the differences. Adverse events will include abdominal pain, 214congestion or runny nose, cough, diarrhea, dizziness, dyspnea, fatigue, fever or chills, headaches, 215hypoxia, loss of appetite, muscle or body aches, nausea, new loss of taste or smell, pruritus, shortness of 216 breath/difficulty breathing, skin rash, sore throat, vomiting, and other. 217 The analysis will be carried out by using SAS and R. 219 220 221